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The Fontan procedure was initially described byFrancis Fontan for the surgical management of
tricuspid atresia in 1971. The principle is diversion
of systemic venous return directly to the pulmonary
arteries in the setting of single ventricle physiology.1
Over subsequent years, many modifications of the
original procedure have been described, although
the basic principle remains the same.2-5 The Fontan
procedure has evolved as the definitive palliative
surgical treatment for most heart lesions when a
biventricular circulation is not feasible.6
Central venous and intracardiac thrombosis are a
major cause of morbidity and mortality after Fontan
procedures. Arterial embolization to the central
nervous system resulting in persistent neurologic
deficits is also a significant complication of Fontan
procedures. Shirai and colleagues in this issue of the
Journal describe a retrospective series of 16 patients
undergoing extracardiac Fontan procedures. The
median follow-up is 13 months, and the incidence of
intracardiac thrombosis is 19%. On the basis of
these findings, the authors have begun routine anti-
thrombotic prophylaxis with aspirin for 6 months
after all Fontan procedures. The usefulness of such
a protocol, as the authors point out, remains to be
proven.
Prophylactic anticoagulation with warfarin or an-
tiplatelet agents after Fontan procedures is fre-
quently recommended.7-9 However, no consensus is
found in the literature or in routine clinical practice
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as to the optimal type or duration of anticoagula-
tion. Consequently, a wide variety of prophylactic
anticoagulant regimens are currently used.10
How does one decide on the most appropriate
therapy? Any decision about instituting preventive
anticoagulation involves a trade-off between bene-
fits (reduced thromboembolism) and toxicity and
cost. Clinical recommendations and treatment
guidelines should be based on the best available
evidence. This is the founding principle of evidence-
based medicine.11 Such an approach begins with a
systematic overview followed by a critical assess-
ment of the existing evidence.12 Assessment of the
literature involves analyzing the strength of study
designs, the validity of the results obtained within
those designs, and the relevance of those results to
the wider patient population.11, 13, 14 Useful mea-
sures of a treatment’s value, such as relative risk
reduction and the number needed to treat (to avoid
one episode of thromboembolism) can then be used
to determine clinical recommendations.12 In other
words, one must assess the strength of the evidence,
the necessary impact of treatment to warrant its use,
and how well the proposed treatment works.12
A comprehensive review of the literature pertain-
ing to thromboembolism after Fontan procedures
reveals no prospective studies or randomized trials.
The current literature consists of cross-sectional
point surveys (n 5 4, however only two directly
assessed thromboembolism), retrospective series in
which thromboembolism was either the primary
outcome measure (n 5 9) or one of multiple out-
comes (n 5 7), and case reports (n 5 15). The
potential for bias in such observational studies,
especially the latter types (multiple outcomes, case
reports), is increased.12-15 Any treatment recom-
mendations based on these studies would be very
weak compared with those obtained from prospec-
tive randomized trials.12, 16
The incidence of thromboembolism after Fontan
procedures is crucial to the appropriateness of pro-
phylactic anticoagulation. Point prevalences for in-
tracardiac thrombosis ranged from 17% to 20% in
the cross-sectional surveys17, 18 (Table I). Reported
incidences of venous thromboembolism and stroke
ranged from 3% to 16% and 3% to 19%, respec-
tively, in the studies in which thromboembolism was
the primary outcome6, 7, 19-25 (Table II) and from
1% to 7% in studies assessing multiple out-
comes1, 3, 26-32 (Table III).
In assessing the validity of incidence estimates
one must consider the diagnostic methods used.33
The most common methods used to detect venous
and intracardiac thrombosis were transthoracic
and transesophageal echocardiography, followed
by angiography. Other diagnostic methods re-
ported included autopsy (11 cases) and reopera-
tion (6 cases). The most common diagnostic meth-
ods used to detect stroke were computed
tomography, magnetic resonance imaging, angiog-
raphy, and clinical diagnosis. The two cross-sec-
Table I. Cross-sectional studies using
transoesophageal echocardiography to assess point
prevalence of thromboembolic events after Fontan
procedures
Author et al.
Patients
in series
No. (%) of
thromboses
Stumper18 18 3 (17)
Fyfe17 30 6 (20)
Table II. Studies that had thromboembolic events
as the primary outcome measure
Author et al.
Patients in
series
(survivors)
No. (%) of
thromboses
Stroke or
arterial emboli:
N (%)
Rosenthal6 70 11 (16) 3 (4)
Jahangiri7 64 (57) 8 (14) 3 (5)
du Plessis19 645 NA 17 (3)
Day20 68 NA 6 (9)
Matthews21 25 (16) NA 3 (19)
Fletcher22 64 6 (9) NA
Dobell23 128 4 (3) NA
Danielson24 449 18 (4) NA
Kaulitz25 72 5 (6) NA
NA, Not assessed.
Table III. Studies in which thromboembolic events
were not the primary otucome measure, but that
gave some details of thromboembolic events
Author et al.
Patients in
series (N)
No. (%) of
thromboses
Stroke or
arterial emboli:
N (%)
Driscoll1 352 3 (1) 4 (1)
Fontan26 100 3 (3) NA
Prenger3 22 2 (7) NA
Laks27 45 1 (2) NA
Annecchino28 38 1 (3) NA
Myers29 34 1 (3) NA
Mair30 65 1 (2) NA
Cromme-Dijkhuis31 37 2 (5) NA
Cromme-Dijkhuis45 66 3 (5) NA
NA, Not assessed.
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tional studies compared transesophageal and
transthoracic echocardiography for intracardiac
thromboembolism.17, 18 Had the point prevalences
from these studies been estimated using transtho-
racic echocardiography, the results would have
been 5% and 3% instead of 17% and 20%. Several
other publications reported thromboembolism di-
agnosed by transesophageal echocardiography or
angiography that were not detected using trans-
thoracic echocardiography.6, 7, 19
In addition to nonstandardized diagnostic tests,
many studies assessed only survivors, with no infor-
mation on mortality. Mean time from Fontan pro-
cedure to thromboembolism was at times greater
than mean time of follow-up.6 The incidence of
thromboembolism was increased in recent studies
compared with earlier studies, reflecting increased
survival, longer duration of follow-up, improved
diagnostic tests, or increased awareness of the po-
tential for thrombosis.6 The retrospective nature of
the studies, frequent lack of sensitive diagnostic
tests, and limited follow-up not only account for
variation in reported incidences but also suggest
that the reported incidences of thromboembolism
after Fontan procedures are minimal estimations.
The timing of thromboembolism after Fontan
procedures is important in determining the optimal
duration of prophylactic anticoagulation. The exact
duration of time from Fontan procedure to throm-
boembolism could be calculated for 109 events
reported in 16 case series3, 7, 17, 19-31 and 15 case
reports.8-10, 32, 34-44 Of these 109 cases of thrombo-
embolism, 54 occurred within the first 3 months
after the procedure and 55 occurred after 3 months.
Two large series that assessed the timing of throm-
boembolism both concluded that the period of risk
extended beyond 3 months after the procedure,6, 7
with a mean time of 6.1 years in one series.6
Prophylactic anticoagulation for 3 months after
Fontan procedures is frequently advocated; how-
ever, it is unjustified on the basis of the existing
literature.
Identification of predisposing factors for throm-
boembolism could allow stratification of patients
into high- or low-risk groups that require different
intensities of prophylactic anticoagulation. A num-
ber of authors have analyzed a variety of possible
predisposing factors, including demographic and
surgical factors (patient age at operation6; type of
Fontan procedure performed,6, 7 including the pres-
ence or absence of fenestration19, 20; type of material
used for the conduit; use of valved or nonvalved
conduits6) and hemodynamic factors (arrhyth-
mias,6, 19, 20 right-to-left shunts,20 polycythemia,19
and low cardiac output24). Although some studies
claimed statistically significant relationships, predis-
posing risk factors were not identified with consis-
tency or certainty because of lack of statistical
power, use of retrospective data, and incomplete
reporting of data. Consequently, no conclusions can
be made about the relative contribution of patient
demographic, surgical, or hemodynamic factors in
causing thromboembolism after Fontan procedures.
Two studies assessed the role of coagulation
deficiencies in the etiology of thromboembolism.
Both studies had major inadequacies.31, 45 The ref-
erence ranges used to determine normal from ab-
normal were not age specific, and most children
labeled as abnormal were in fact normal for age.
Case reports with similar findings also used inappro-
priate reference ranges, whereas cases reporting
normal coagulation factors did not.6, 20, 25, 37 No
Table IV. Outcome of thromboembolic events after Fontan procedures according to antithrombotic treatment
Treatment
Number
treated
Outcome of treatment
Successful
Treatment failure
Complete
resolution Death
Subsequent embolization,
extension, or incomplete
resolution
Subsequent
takedown
of Fontan
Surgery 4 1 2 1 —
Surgery 1 anticoagulation 14 7 6 — 1
Thrombolysis 6 3 1 3 —
Thrombolysis 1 anticoagulation 11 3 4 8 —
Heparin 5 3 1 1 —
Coumadin 23 14 2 7 1
Aspirin 2 — — 2 —
Total 65 31 16 22 2
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 3
Monagle et al. 4 9 5
accurate data implicate abnormalities of the coagu-
lation system in thromboembolism after Fontan
procedures.
All episodes of thromboembolism in the series by
Shirai and colleagues were detected on routine
transthoracic echocardiographic screening of
asymptomatic patients. Warfarin therapy was begun
and the patients remained well, although the dura-
tion of follow-up was not stated. Routine evaluation
with transthoracic echocardiography leading to the
detection and treatment of asymptomatic thrombi
has previously been reported to improve outcome
and reduce the incidence of stroke.6 However, other
cases are reported in which subsequent stroke was
not prevented.17, 19 Prospective studies are required
to confirm the usefulness of routine screening, in
particular with a sensitive test such as transesopha-
geal echocardiography.46, 47
The management of thromboembolism after Fon-
tan procedures is also controversial. Literature on
the management and outcome of thromboembolism
was scarce and often poorly documented (Table
IV). Therapeutic options include surgical embolec-
tomy, with or without further surgical modifications
of the intracardiac anatomy; thrombolytic therapy;
and anticoagulation therapy. Total resolution of
thrombosis was achieved in only 48% of cases.
Death occurred in 25% despite aggressive treat-
ment.* Many children do not survive long enough to
be given effective antithrombotic treatment.38
The incidence and poor prognosis of thromboem-
bolism after Fontan procedures has caused most
authors to postulate that routine prophylactic anti-
coagulation with warfarin or antiplatelet agents is
warranted. However, only one small retrospective
series has been published in which all patients
received prophylactic anticoagulation. Despite war-
farin administration for 3 months, the incidence of
venous thrombosis alone was 7.4%.3 The target
international normalized ratio, which reflects the
level of anticoagulation, was not stated. In total,
from all other case series and reports in the litera-
ture, only 16 patients received prophylactic antico-
agulation therapy with either warfarin (n 5 12),
aspirin (n 5 3), or heparin (n 5 1).6, 7, 10, 17, 19, 20, 25, 35
The rationale for prophylaxis in these particular
patients was the presence of fenestration (n 5 7),
previous thrombosis (n 5 2), atrial fibrillation (n 5
1), and immobility (n 5 1). No rationale was given
for a further five cases. Of the 12 patients who
received warfarin (target international normalized
ratios not stated), five had thromboembolism during
or after the prophylactic therapy. In one patient
warfarin was discontinued because of bleeding and a
subsequent thromboembolus occurred.35 The three
patients given prophylactic aspirin and one patient
given heparin all had thromboemboli while receiv-
ing prophylactic therapy. In summary, the usefulness
of prophylactic anticoagulation therapy remains to
be proven. Virtually no information regarding the
safety and efficacy of prophylactic anticoagulation
with oral anticoagulants or antiplatelet agents exists.
The current study by Shirai and colleagues is
useful because it reaffirms the high risk of thrombo-
embolism after Fontan procedures. With increased
follow-up and using a more sensitive diagnostic
method like transesophageal echocardiography, the
incidence of thromboembolism after Fontan proce-
dures is likely greater than 20%. In combination
with the reported poor outcome of thromboembo-
lism, prophylaxis seems logical. The optimal type
and duration of any such therapy is unknown.
Returning to our framework of evidence-based
medicine, we can find little evidence documenting
the benefits or risks of routine prophylaxis. Mea-
sures such as relative risk and number needed to
treat cannot be applied because the appropriate
studies have not been done. Current practices can
only be viewed as opinions based, at best, on theory
and personal experiences. As we approach the next
millennium, this level of evidence is insufficient
grounds for management of an important issue that
has remained unresolved for 25 years. By design,
retrospective case series like that of Shirai and
colleagues and those published previously cannot
resolve this issue.15 These questions can only be
answered in well-controlled, prospective stud-
ies.13, 14 Single institutions are unlikely to success-
fully complete such studies. Multicenter randomized
controlled trials comparing prophylactic antiplatelet
and anticoagulation therapies are urgently required
to provide rational scientific guidelines for the fu-
ture management of Fontan procedures in children.
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